DARATUMUMAB PLUS LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE IN
PATIENTS WITH TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA:
UPDATED ANALYSIS OF GRIFFIN AFTER 12 MONTHS OF MAINTENANCE THERAPY
Peter M. Voorhees1, Jacob Laubach2, Douglas W. Sborov3, Brandi Reeves4, Cesar Rodriguez5, Ajai
Chari6, Rebecca Silbermann7, Luciano J. Costa8, Larry D. Anderson Jr.9, Nitya Nathwani10, Nina Shah11,
Yvonne A. Efebera12, Sarah A. Holstein13, Caitlin Costello14, Andrzej Jakubowiak15, Tanya M. Wildes16,
Robert Z. Orlowski17, Kenneth H. Shain18, Andrew J. Cowan19, Yana Lutska20, Padma Bobba20, Huiling
Pei21, Jon Ukropec22, Jessica Vermeulen23, Thomas S. Lin20, Paul G. Richardson2 and Jonathan L.
Kaufman24
(1)Levine Cancer Institute, Atrium Health, Charlotte, NC
(2)Dana-Farber Cancer Institute, Boston, MA
(3)Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
(4)University of North Carolina – Chapel Hill, Chapel Hill, NC
(5)Wake Forest University School of Medicine, Winston-Salem, NC
(6)Tisch Cancer Institute, Mount Sinai School of Medicine, New York, NY
(7)Knight Cancer Institute, Oregon Health & Science University, Portland, OR
(8)University of Alabama at Birmingham, Birmingham, AL
(9)Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
(10)Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive
Cancer Center, Duarte, CA
(11)Department of Medicine, University of California San Francisco, San Francisco, CA
(12)The Ohio State University Comprehensive Cancer Center, Columbus, OH
(13)Division of Oncology & Hematology, University of Nebraska Medical Center, Omaha, NE
(14)Moores Cancer Center, University of California San Diego, La Jolla, CA
(15)University of Chicago Medical Center, Chicago, IL
(16)Division of Oncology, Section Medical Oncology, Washington University School of Medicine, St.
Louis, MO
(17)Department of Lymphoma-Myeloma, The University of Texas M.D. Anderson Cancer Center,
Houston, TX
(18)Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL
(19)Division of Medical Oncology, University of Washington, Seattle, WA
(20)Janssen Scientific Affairs, LLC, Horsham, PA
(21)Janssen Research & Development, LLC, Titusville, NJ
(22)Janssen Global Medical Affairs, Horsham, PA
(23)Janssen Research & Development, LLC, Leiden, Netherlands
(24)Winship Cancer Institute, Emory University, Atlanta, GA
Objectives: Daratumumab, a CD38-targeting human IgGκ monoclonal antibody, is approved as
monotherapy and in combination with standard-of-care regimens for the treatment of newly
diagnosed multiple myeloma (NDMM) and relapsed/refractory MM. Treatment with daratumumab
plus lenalidomide (R)/bortezomib (V)/dexamethasone (d) (D-RVd) in phase 2 GRIFFIN (NCT02874742)
significantly improved rates of stringent complete response (sCR) by end of post-transplant
consolidation therapy in patients with transplant-eligible NDMM vs RVd alone. Updated efficacy and
safety results following 12-month maintenance with R or daratumumab+R (D-R) are presented.
Methods: Patients with NDMM eligible for high-dose therapy and autologous stem cell transplant
(ASCT) were randomly assigned (1:1) to receive daratumumab±RVd induction (4 cycles), high-dose
therapy, ASCT, consolidation (2 cycles), and maintenance with daratumumab±R (24 months). During